18F-TFB PET与131I显像在分化型甲状腺癌中的诊断效能前瞻性研究
该前瞻性研究纳入58例分化型甲状腺癌术后患者,比较18F-TFB PET与131I闪烁显像的诊断效能及生物分布。患者层面两种方法总体一致性好(κ=0.75),碘前组几乎完美(κ=0.84),碘后组降至中等(κ=0.49);病灶检出率TFB在碘前组显著更高(95.7% vs 68.1%,p<0.05)。TFB PET诊断效能与131I显像相当,碘前更优,碘后可能受顿抑效应影响。
要点
- TFB PET与131I显像患者层面总体一致性高,碘前组优于碘后组。
- 碘前组病灶检出率TFB显著高于131I(95.7% vs 68.1%,p<0.05)。
- 碘后组病灶检出率降至33.3%,提示131I顿抑效应影响TFB摄取。
核心结论
- TFB PET在分化型甲状腺癌中诊断准确性和病灶检出率与131I闪烁显像相当。
- 近期未接受放射性碘治疗的患者,TFB PET诊断效能更优。
- 放射性碘治疗后TFB病灶可检测性下降,可能源于顿抑效应。
研究设计与样本
- 前瞻性研究纳入58例病理确诊分化型甲状腺癌全切或近全切术后患者。
- 按近期是否接受放射性碘分为碘前组(n=28)和碘后组(n=20),行患者和病灶层面分析,一致性用Cohen kappa评估。
主要发现
- 患者层面:TFB与131I均阳性20例,仅TFB阳性1例,仅131I阳性5例,均阴性22例,总体一致性κ=0.75。
- 碘前组一致性几乎完美(κ=0.84),碘后组降至中等(κ=0.49)。
- 病灶层面(n=56)总体检出率TFB 85.7% vs 131I 73.2%,碘前组TFB显著更高(95.7% vs 68.1%,p<0.05)。
- 碘后组病灶检出率降至33.3%,与顿抑效应一致。
- 生物分布显示胃、唾液腺、食管、鼻咽部生理性摄取最高,45%女性患者见意外子宫颈纳氏囊肿摄取。
关键数值与推荐
- 患者层面一致性κ=0.75,碘前组κ=0.84,碘后组κ=0.49。
- 病灶层面总体检出率TFB 85.7% vs 131I 73.2%。
- 碘前组病灶检出率TFB 95.7% vs 131I 68.1%(p<0.05)。
- 碘后组病灶检出率33.3%。
- 45%女性患者见子宫纳氏囊肿摄取。
临床怎么用
- TFB PET可作为分化型甲状腺癌疾病负荷评估的替代显像方法。
- 建议在近期未接受放射性碘治疗的患者中优先考虑TFB PET。
- 放射性碘治疗后短期内行TFB PET需考虑顿抑效应导致的检出率下降。
局限性
- 单中心前瞻性研究,样本量有限(58例)。
- 碘后组样本量较小(n=20),一致性结果需谨慎解读。
- 结论需进一步多中心验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Differentiated thyroid cancer (DTC) is primarily evaluated using radioiodine (RAI) scanning; however, this approach is limited by the suboptimal imaging properties of 131I, the cost and limited availability of 123I, and restricted access to 124I. [18F]Tetrafluoroborate (TFB), a PET radiotracer targeting the sodium/iodide symporter, has emerged as a promising alternative. This prospective study assessed the diagnostic performance and biodistribution of TFB PET compared with 131I scintigraphy in patients with DTC. METHODS: This prospective study enrolled 58 patients with histopathologically confirmed DTC after total or near-total thyroidectomy. Forty-eight patients underwent both TFB PET/CT and 131I SPECT scintigraphy, while 10 underwent only TFB PET for biodistribution analysis. Patients were stratified into preradioiodine (TFB before 131I; n = 28) and postradioiodine (TFB after 131I; n = 20) subgroups based on recent radioiodine administration (either diagnostic or therapeutic) to evaluate the potential stunning effect of 131I on TFB uptake. Patient- and lesion-based analyses were performed, and agreement was assessed using Cohen's kappa. RESULTS: In patient-based analysis, concordance between modalities showed both TFB and 131I positivity in 20 patients, TFB-only positivity in 1 patient, 131I-only positivity in 5 patients, and negativity in both modalities in 22 patients, yielding substantial overall agreement (κ = 0.75). Agreement was almost perfect in the preradioiodine group (κ = 0.84) but declined to a moderate level in the postradioiodine group (κ = 0.49). In lesion-based analysis (n = 56), overall detection rates were comparable (TFB, 85.7% vs. 131I, 73.2%) but significantly higher for TFB in the preradioiodine group (95.7% vs. 68.1%, p < 0.05). Lesion detection decreased markedly in the postradioiodine group (33.3%), consistent with a stunning effect. Biodistribution analysis showed highest physiological uptake in the stomach, salivary glands, esophagus, nasopharynx and unexpected uterine uptake in Nabothian cysts in 45% of female patients. CONCLUSION: TFB PET demonstrates diagnostic accuracy and lesion detection rates comparable to 131I scintigraphy in DTC. Its diagnostic performance is superior in patients without recent radioiodine administration prior to TFB imaging, whereas lesion detectability decreases after radioiodine administration, likely due to a stunning effect. Therefore, TFB PET represents a promising alternative for disease burden assessment in DTC and warrants further multicenter validation.
引用
- Sonmezoglu K, Sahin OE, Saglam K, et al. Diagnostic performance of [18F]Tetrafluoroborate PET versus 131I scintigraphy in differentiated thyroid cancer: a prospective study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42189228. doi:10.1007/s00259-026-07945-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。